文献速递神经肿瘤小儿神经外科与脑积水

免疫调节抗体MDV9300(pidilizumab)治疗儿童弥漫性内生型脑桥胶质瘤的初步结果

Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma.
PubMed 文献 · J Neurooncol · 2017-11-15

研究纳入以色列2014年2月至2015年6月诊断为弥漫性内生型脑桥胶质瘤(DIPG)的13名儿童中的9名,放疗结束后每两周给予6 mg/kg MDV9300直至影像学进展。主要副作用为中性粒细胞减少(CTCAE 1-3级)、轻中度疲乏和急性血压升高。中位无事件生存期9.3个月(范围6.8-24),中位总生存期15.6个月(范围6.9-28)。初步结果示MDV9300治疗安全且可能有效。

要点

  • 9名DIPG患儿放疗后接受每两周6 mg/kg MDV9300治疗,共83个周期。
  • 中位无事件生存期9.3个月(范围6.8-24),中位总生存期15.6个月(范围6.9-28)。
  • 主要副作用为中性粒细胞减少(CTCAE 1-3级)、轻中度疲乏和急性血压升高。

核心结论

  • 初步结果示MDV9300治疗对DIPG患儿安全且可能有效。

研究设计与样本

  • 首个评估免疫调节抗体MDV9300在儿童DIPG患者中应用的研究。
  • 研究期间以色列2014年2月至2015年6月诊断为DIPG的13名3岁及以上儿童均被邀请参与,最终9名入组。

主要发现

  • 入组患儿完成放疗后开始每两周6 mg/kg MDV9300治疗,直至影像学疾病进展,共应用83个周期(范围2-16)。
  • 所有患儿接受放疗,均未接受化疗。
  • 主要副作用为中性粒细胞减少(CTCAE 1-3级)、轻中度疲乏和急性血压升高。
  • 4名患儿在诊断后1年内死亡,另3名在2年内死亡,2名患儿在诊断后近30个月时仍存活且疾病稳定。
  • 中位无事件生存期为9.3个月(范围6.8-24),中位总生存期为15.6个月(范围6.9-28)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse intrinsic pontine glioma (DIPG) is an incurable disease with a median overall survival of 10 months. Immune modulating antibodies have recently emerged as a highly promising treatment modality in multiple cancer types. We present results from the first study to evaluate the immune modulating antibody MDV9300 (pidilizumab) in pediatric patients with DIPG. All patients aged 3 years and older, diagnosed with DIPG between February 2014 and June 2015 in Israel, were offered to participate in the study. Enrolled patients were started on biweekly 6 mg/kg MDV9300 after radiation completion. Treatment was continued until disease progression on imaging. Patients were followed biweekly for the occurrence of neurological deficit toxicities and side effects. Secondary endpoints were event free survival and overall survival. Of 13 children diagnosed with DIPG during the study period, nine were enrolled in the study. The patients underwent radiotherapy and none had chemotherapy. A total of 83 cycles of MDV9300 (range 2-16) were applied. The main side effects were neutropenia (CTCAE grade 1-3), mild to moderate fatigue, and acute elevation of blood pressure. Four patients died within 1 year of the diagnosis, another three died within 2 years and two children are still alive nearly 30 months from diagnosis, with stable disease. The median event free survival is 9.3 months (range 6.8-24) and the median overall survival is 15.6 months (range 6.9-28). Preliminary results demonstrate that MDV9300 treatment is safe and may be effective in the treatment of children with DIPG.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Fried I, Lossos A, Ben Ami T, et al. Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma. J Neurooncol. 2017. PMID: 29143272. doi:10.1007/s11060-017-2643-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。